U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C25H29BrF3N5O.2ClH
Molecular Weight 625.352
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ATC-0065

SMILES

Cl.Cl.CN(C)C1=NC(N[C@@H]2CC[C@@H](CC2)NCCC3=CC=C(Br)C=C3OC(F)(F)F)=NC4=C1C=CC=C4

InChI

InChIKey=BPGUWYBAINNZQH-LFOVFOEYSA-N
InChI=1S/C25H29BrF3N5O.2ClH/c1-34(2)23-20-5-3-4-6-21(20)32-24(33-23)31-19-11-9-18(10-12-19)30-14-13-16-7-8-17(26)15-22(16)35-25(27,28)29;;/h3-8,15,18-19,30H,9-14H2,1-2H3,(H,31,32,33);2*1H/t18-,19+;;

HIDE SMILES / InChI

Molecular Formula C25H29BrF3N5O
Molecular Weight 552.43
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 2 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

ATC-0065 is an oral antagonist of melanin concentrating hormone receptor 1. In preclinical testing ATC-0065 demonstrated anxiolytic and antidepressant activity.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
15.7 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
ATC-0065 is administered orally at a dose of 3–30 mg/kg (rat model).
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
3Q2C0BZD71
Record Status Validated (UNII)
Record Version